TY - JOUR
T1 - Exogenous nitric oxide reduces oxygen consumption of isolated ventricular myocytes less than other forms of guanylate cyclase stimulation
AU - Gong, Gary X.
AU - Weiss, Harvey R.
AU - Tse, James
AU - Scholz, Peter M.
N1 - Funding Information:
This study was supported, in part, by U.S.P.H.S. grant HL40320 and a grant-in-aid from the American Heart Association, New Jersey Affiliate.
PY - 1998/3/5
Y1 - 1998/3/5
N2 - We tested the hypothesis that increasing cyclic GMP with nitric oxide (NO) would reduce cardiac myocyte metabolism less than other forms of guanylate cyclase stimulation. The steady state O2 consumption (VO2) of a suspension of ventricular myocytes in 2.0 mM Ca2+ isolated from hearts of New Zealand white rabbits was measured in a glass chamber using Clark-type oxygen electrode. The cellular cyclic GMP levels, determined by radioimmunoassay, were increased by (1) adding 3-morpholinosydnonimine (SIN- 1, 10-8-10-5 M) and nitroprusside (10-8-10-5 M), NO donors-soluble guanylate cyclase stimulators; (2) carbon monoxide (CO, 1.5 x 10-8-1.5 x 10-6 M), soluble guanylate cyclase stimulator and (3) guanylin (10-8- 10-5 M), particulate gunnylate cyclase stimulator. The baseline myocyte cyclic GMP level was 86 ± 13 fmol/105 myocytes with a corresponding VO2 of 268 ± 21 nl O2/min per 105 myocytes. An inverse relationship between cellular cyclic GMP levels and VO2 existed in these myocytes. The regression equations for the four treatments were: VO2 = -0.45 x [cyclic GMP] + 294.4, r = 0.94 for SIN-1; VO2 = -1.46 x [cyclic GMP] + 444.7, r = 0.96 for CO; VO2 = -1.25 x [cyclic GMP] + 389.1, r = 0.84 for guanylin and VO2 = -0.55 x [cyclic GMP] + 322.8, r = 0.79 for nitroprusside. The regression lines of the two NO donors were parallel. A similar result was also evident for the regressions of CO and guanylin. However, the slopes of both the SIN-1 and nitroprusside regression line were significantly less steep than that of either the CO or guanylin lines. Therefore, VO2 is reduced less for a similar increase in cyclic GMP with NO donors compared to direct stimulation with CO or guanylin. These results suggest that NO has metabolic effects on myocytes in addition to its stimulatory effects on cellular cyclic GMP.
AB - We tested the hypothesis that increasing cyclic GMP with nitric oxide (NO) would reduce cardiac myocyte metabolism less than other forms of guanylate cyclase stimulation. The steady state O2 consumption (VO2) of a suspension of ventricular myocytes in 2.0 mM Ca2+ isolated from hearts of New Zealand white rabbits was measured in a glass chamber using Clark-type oxygen electrode. The cellular cyclic GMP levels, determined by radioimmunoassay, were increased by (1) adding 3-morpholinosydnonimine (SIN- 1, 10-8-10-5 M) and nitroprusside (10-8-10-5 M), NO donors-soluble guanylate cyclase stimulators; (2) carbon monoxide (CO, 1.5 x 10-8-1.5 x 10-6 M), soluble guanylate cyclase stimulator and (3) guanylin (10-8- 10-5 M), particulate gunnylate cyclase stimulator. The baseline myocyte cyclic GMP level was 86 ± 13 fmol/105 myocytes with a corresponding VO2 of 268 ± 21 nl O2/min per 105 myocytes. An inverse relationship between cellular cyclic GMP levels and VO2 existed in these myocytes. The regression equations for the four treatments were: VO2 = -0.45 x [cyclic GMP] + 294.4, r = 0.94 for SIN-1; VO2 = -1.46 x [cyclic GMP] + 444.7, r = 0.96 for CO; VO2 = -1.25 x [cyclic GMP] + 389.1, r = 0.84 for guanylin and VO2 = -0.55 x [cyclic GMP] + 322.8, r = 0.79 for nitroprusside. The regression lines of the two NO donors were parallel. A similar result was also evident for the regressions of CO and guanylin. However, the slopes of both the SIN-1 and nitroprusside regression line were significantly less steep than that of either the CO or guanylin lines. Therefore, VO2 is reduced less for a similar increase in cyclic GMP with NO donors compared to direct stimulation with CO or guanylin. These results suggest that NO has metabolic effects on myocytes in addition to its stimulatory effects on cellular cyclic GMP.
KW - (Rabbit)
KW - CGMP
KW - Cardiac myocyte
KW - Guanylate cyclase stimulation
KW - Nitric oxide (NO)
KW - Oxygen consumption
UR - http://www.scopus.com/inward/record.url?scp=0032485510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032485510&partnerID=8YFLogxK
U2 - 10.1016/S0014-2999(97)01593-8
DO - 10.1016/S0014-2999(97)01593-8
M3 - Article
C2 - 9600666
AN - SCOPUS:0032485510
SN - 0014-2999
VL - 344
SP - 299
EP - 305
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2-3
ER -